The effects of preventative cannabidiol in a male neuregulin 1 mouse model of schizophrenia

The effects of preventative cannabidiol in a male neuregulin 1 mouse model of schizophrenia

Cannabidiol (CBD) is a non-intoxicating cannabinoid with antipsychotic-like properties, however it’s potential to prevent schizophrenia development has not been thoroughly investigated. Brain maturation during adolescence creates a window where CBD could potentially limit the development of schizoph...

Full description

Bibliographic Details
Main Authors:	Gabriela Visini, Samara Brown, Katrina Weston-Green, Cynthia Shannon Weickert, Rose Chesworth, Tim Karl
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-11-01
Series:	Frontiers in Cellular Neuroscience
Subjects:	cannabidiol (CBD) Δ9-tetrahydrocannabinol (THC) behavior brain pathology neuregulin 1
Online Access:	https://www.frontiersin.org/articles/10.3389/fncel.2022.1010478/full

Similar Items

Cannabis, Cannabidiol Oils and Tetrahydrocannabinol—What Do Veterinarians Need to Know?
by: Nancy De Briyne, et al.
Published: (2021-03-01)

The Role of Cannabinoids as Anticancer Agents in Pediatric Oncology
by: Clara Andradas, et al.
Published: (2021-01-01)

Implications of marijuana use prior to anesthetic care.
by: K. Stone, et al.
Published: (2023-01-01)

Endocannabinoid System as Therapeutic Target of PTSD: A Systematic Review
by: Luca Steardo, et al.
Published: (2021-03-01)

Characteristics of Older Adults Who Were Early Adopters of Medical Cannabis in the Florida Medical Marijuana Use Registry
by: Joshua D. Brown, et al.
Published: (2020-04-01)

Pharmacokinetics of Orally Applied Cannabinoids and Medical Marijuana Extracts in Mouse Nervous Tissue and Plasma: Relevance for Pain Treatment
by: Cristiana Dumbraveanu, et al.
Published: (2023-03-01)

Antidepressant and Anxiolytic Effects of Medicinal Cannabis Use in an Observational Trial
by: Erin L. Martin, et al.
Published: (2021-09-01)

Cure-All cannabidiol? The cannabidiol content of commercial products
by: Michaela Mouton, et al.
Published: (2024-02-01)

THC-Reduced <i>Cannabis sativa</i> L.—How Does the Solvent Determine the Bioavailability of Cannabinoids Given Orally?
by: Joanna Bartkowiak-Wieczorek, et al.
Published: (2023-06-01)

The Desert Whale: the boom and bust of hemp in Arizona
by: Anastasia K. Stats, et al.
Published: (2023-06-01)

Potential effects of cannabinoids on audiovestibular function: A narrative review
by: Joaquin Guerra, et al.
Published: (2022-12-01)

Cannabinoids accumulate in mouse breast milk and differentially regulate lipid composition and lipid signaling molecules involved in infant development
by: Clare T Johnson, et al.
Published: (2022-01-01)

A cannabis oracle? Delphi method not a substitute for randomized controlled trials of cannabinoids as therapeutics
by: Kevin P. Hill, et al.
Published: (2021-07-01)

Investigating Relationships Between Alcohol and Cannabis Use in an Online Survey of Cannabis Users: A Focus on Cannabinoid Content and Cannabis for Medical Purposes
by: Hollis C. Karoly, et al.
Published: (2020-12-01)

Consensus recommendations on dosing and administration of medical cannabis to treat chronic pain: results of a modified Delphi process
by: Arun Bhaskar, et al.
Published: (2021-07-01)

Medical Cannabis Activity Against Inflammation: Active Compounds and Modes of Action
by: Seegehalli M. Anil, et al.
Published: (2022-05-01)

Evaluation of two different Cannabis sativa L. extracts as antioxidant and neuroprotective agents
by: Guillermo Cásedas, et al.
Published: (2022-09-01)

Therapeutic properties of multi-cannabinoid treatment strategies for Alzheimer’s disease
by: Madilyn Coles, et al.
Published: (2022-09-01)

Using the BMD Approach to Derive Acceptable Daily Intakes of Cannabidiol (CBD) and Tetrahydrocannabinol (THC) Relevant to Electronic Cigarette Liquids
by: Pascal Hindelang, et al.
Published: (2022-07-01)

Effects of Oral Cannabinoids on Systemic Inflammation and Viral Reservoir Markers in People with HIV on Antiretroviral Therapy: Results of the CTN PT028 Pilot Clinical Trial
by: Ralph-Sydney Mboumba Bouassa, et al.
Published: (2023-07-01)

Measurement of Δ9THC and metabolites in the brain and peripheral tissues after intranasal instillation of a nanoformulation
by: Gunjan Upadhyay, et al.
Published: (2023-02-01)

Pharmacokinetic of two oral doses of a 1:20 THC:CBD cannabis herbal extract in cats
by: Chloe Lyons, et al.
Published: (2024-02-01)

Legalization of marijuana or not? Opinions from over 38,000 residents in Taiwan
by: Kuo-Yu Chao, et al.
Published: (2023-10-01)

Online survey of medicinal cannabis users: Qualitative analysis of patient-level data
by: Albert Garcia-Romeu, et al.
Published: (2022-09-01)

Preliminary Investigation of the Safety of Escalating Cannabinoid Doses in Healthy Dogs
by: Dana Vaughn, et al.
Published: (2020-02-01)

Differential effects of cannabis constituents on schizophrenia-related psychosis: a rationale for incorporating cannabidiol into a schizophrenia therapeutic regimen
by: Kennadi Johnson, et al.
Published: (2024-04-01)

Use of non-medical cannabis in epilepsy: A scoping review
by: Jimmy Li, et al.
Published: (2023-03-01)

Pharmacokinetic and Safety Evaluation of Various Oral Doses of a Novel 1:20 THC:CBD Cannabis Herbal Extract in Dogs
by: Alan Chicoine, et al.
Published: (2020-09-01)

Comparative Metabolomic Profiling of the Metabolic Differences of Δ9-Tetrahydrocannabinol and Cannabidiol
by: Qianru Rao, et al.
Published: (2022-11-01)

A Review on Studies of Marijuana for Alzheimer’s Disease – Focusing on CBD, THC
by: Seok Hee Kim, et al.
Published: (2019-12-01)

Safety and Tolerability of Oral Cannabinoids in People Living with HIV on Long-Term ART: A Randomized, Open-Label, Interventional Pilot Clinical Trial (CTNPT 028)
by: Ralph-Sydney Mboumba Bouassa, et al.
Published: (2022-12-01)

Direct Quantitation of Phytocannabinoids by One-Dimensional <sup>1</sup>H qNMR and Two-Dimensional <sup>1</sup>H-<sup>1</sup>H COSY qNMR in Complex Natural Mixtures
by: Evangelos Dadiotis, et al.
Published: (2022-05-01)

Phytocannabinoids and Cannabis-Based Products as Alternative Pharmacotherapy in Neurodegenerative Diseases: From Hypothesis to Clinical Practice
by: Yolanda Paes-Colli, et al.
Published: (2022-05-01)

Hemp in Veterinary Medicine: From Feed to Drug
by: Giorgia della Rocca, et al.
Published: (2020-07-01)

Does cannabidiol protect against adverse psychological effects of THC?
by: Raymond J.M. eNiesink, et al.
Published: (2013-10-01)

Optimal condition of cannabis maceration to obtain the high cannabidiol and Δ9-tetrahydrocannabinol content
by: CHAOWALIT MONTON, et al.
Published: (2019-10-01)

Effect of long-term cannabidiol on learning and anxiety in a female Alzheimer’s disease mouse model
by: Rose Chesworth, et al.
Published: (2022-09-01)

A Quantitative <sup>1</sup>H NMR Method for Screening Cannabinoids in CBD Oils
by: Ines Barthlott, et al.
Published: (2021-06-01)

Simultaneous Quantification of 17 Cannabinoids in Cannabis Inflorescence by Liquid Chromatography-Mass Spectrometry
by: Amitha K. Hewavitharana, et al.
Published: (2022-03-01)

Cannabinoids and Chronic Liver Diseases
by: Ralph-Sydney Mboumba Bouassa, et al.
Published: (2022-08-01)